Joint (NASDAQ:JYNT) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Wall Street Zen upgraded shares of Joint (NASDAQ:JYNT) from a buy rating to a strong-buy rating in a report released on Saturday.

Other equities analysts have also issued research reports about the company. Zacks Research lowered Joint from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded Joint from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, June 12th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Joint has a consensus rating of “Hold”.

Joint Stock Up 1.3%

JYNT stock opened at $8.33 on Friday. The company’s 50-day moving average price is $8.76 and its two-hundred day moving average price is $8.87. The firm has a market cap of $118.79 million, a P/E ratio of 30.85 and a beta of 1.10. Joint has a 12 month low of $7.50 and a 12 month high of $11.26.

Joint (NASDAQ:JYNT) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. The company had revenue of $15.18 million during the quarter, compared to the consensus estimate of $14.57 million. Joint had a net margin of 6.49% and a return on equity of 11.70%. Equities analysts predict that Joint will post 0.51 EPS for the current year.

Insider Activity at Joint

In other Joint news, major shareholder Charles E. Jobson purchased 127,676 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were bought at an average price of $8.57 per share, for a total transaction of $1,094,183.32. Following the completion of the acquisition, the insider owned 1,773,479 shares in the company, valued at approximately $15,198,715.03. This trade represents a 7.76% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 30.20% of the company’s stock.

Institutional Trading of Joint

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its position in Joint by 17.6% during the 2nd quarter. Geode Capital Management LLC now owns 345,330 shares of the company’s stock worth $3,986,000 after purchasing an additional 51,704 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Joint by 32.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock valued at $86,000 after buying an additional 1,810 shares during the last quarter. Rhumbline Advisers grew its position in shares of Joint by 25.9% in the 2nd quarter. Rhumbline Advisers now owns 20,934 shares of the company’s stock valued at $242,000 after buying an additional 4,307 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Joint by 13.9% in the second quarter. American Century Companies Inc. now owns 27,572 shares of the company’s stock valued at $318,000 after buying an additional 3,366 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Joint by 25.9% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock valued at $95,000 after buying an additional 1,698 shares during the period. 76.88% of the stock is currently owned by institutional investors and hedge funds.

About Joint

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.